New And Special Drugs
Atled (Fanregratinib) – Intrahepatic Cholangiocarcinoma | HongKong DengYue Medicine
Redemplo (Plozasiran) – FCS | HongKong DengYue Medicine
Yizekang (Izalontamab Brengitecan) – NPC/ESCC | HongKong DengYue Medicine
Qiyoukang (Gumokimab) – Plaque Psoriasis | HongKong DengYue Medicine
Lukeda (Rocbrutinib) – MCL | HongKong DengYue Medicine
Epkinly (Epcoritamab) – Follicular Lymphoma | HongKong DengYue Medicine
Blenrep (Belantamab Mafodotin) – Multiple Myeloma | HongKong DengYue Medicine
Hyrnuo (Sevabertinib) – NSCLC | HongKong DengYue Medicine
What Can We Offer You?
Generic drugs
Dedicated to providing high-quality, affordable medicines around the world
Vitamins and Supplements
A balanced diet by addressing different deficiencies with the right dosage
brand name medicines
DengYue Medicine as China Drug Import and Export Wholesaler, fills the gap between quality and quantity by adding some affordability
Fast-moving consumer goods
Stock a full range of products from sanitary napkins to foot care creams for your daily needs
non-prescription drugs
Flagship OTC brand - approved and accepted by global standards
Medical supplies and auxiliary supplies
Explore continually updated supplies, diagnostic equipment and essential tools
News
HongKong DengYue Medicine Wholesaler focus on medical trends and obtain new drug directions.
China Innovative Oncology Drugs: 15 New Approvals in H1 2026
According to publicly available information, 38 innovative drugs were approved for marketing in China in the first half of 2026, including 31 domestically developed innovative
Felzartamab Approved for Multiple Myeloma: Another CD38 Monoclonal Antibody Enters the Chinese Market
Felzartamab is a CD38-targeting human monoclonal antibody, with Felzartamab approved for multiple myeloma in China and under clinical development for IgA nephropathy, primary membranous nephropathy,
Tinengotinib Approved for Cholangiocarcinoma in China, Addressing FGFR Inhibitor Resistance
Tinengotinib approved for cholangiocarcinoma marks an important advance for patients with FGFR2 fusion or rearrangement-positive disease who have progressed after FGFR inhibitor therapy. As a
Breast Cancer Drug List in China: Common Endocrine, Targeted, ADC, and Chemotherapy Drugs
The breast cancer drug list in China mainly includes endocrine therapy drugs, HER2-targeted drugs, CDK4/6 inhibitors, mTOR inhibitors, PARP inhibitors, antibody-drug conjugates (ADCs), chemotherapy drugs,
How to Identify the Early Signs of Melanoma: The ABCDE Rule and Warning Signs
Key Takeaways Melanoma is a malignant tumor that originates from melanocytes and most commonly develops in the skin. So, how to identify the early signs
What Are the Most Common Chemotherapy Drugs? 10 Frequently Used Medications
What are the most common chemotherapy drugs? Common chemotherapy drugs include Cisplatin, Carboplatin, Oxaliplatin, Paclitaxel, Docetaxel, Gemcitabine, Pemetrexed, Fluorouracil (5-FU), Capecitabine, and Irinotecan. Chemotherapy is
Recibokibart Approved for GPP: China-Developed IL-36R Antibody Brings a New Treatment Option for Generalized Pustular Psoriasis
Recibokibart approved for GPP marks a major milestone in Generalized Pustular Psoriasis (GPP) treatment. Developed by Shanghai Huaota Biopharmaceutical Co., Ltd., this IL-36R monoclonal antibody
Insulin Sudelidec Approved for Type 2 Diabetes in China: A New Chinese Innovation in the Long-Acting Basal Insulin Market
Insulin Sudelidec approved for type 2 diabetes in China following NMPA approval for adults with type 2 diabetes. Key Phase III studies demonstrated comparable glucose-lowering
Fast And Safe Delivery
Global Transportation Express
Temperature-controlled Transport
Safe Transportation, GDP Compliant
